BioCentury
ARTICLE | Clinical News

CereSpir's itanapraced reduces neurotoxicity in PD model

January 11, 2019 5:26 PM UTC

CereSpir Inc. (New York, N.Y.) reported on Dec. 10 that lead product itanapraced (CSP-1103) reduced neurotoxicity in a mouse model of Parkinson’s disease and in cultured neurons from the model. The company said the data support Phase II trials of the candidate for PD that are slated to start this year.

Although itanapraced has been evaluated in Phase II testing for mild cognitive impairment (MCI) and Alzheimer's disease, CereSpir founder and CSO Daniel Chain told BioCentury the company chose not to pursue AD due to the cost and complexity of conducting late-stage clinical trials in the indication...